We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

43 hedge funds and large institutions have $77.9M invested in Adaptimmune Therapeutics in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.51% less ownership

Funds ownership: 10.84% → 10.32% (-0.51%)

12% less funds holding

Funds holding: 49 → 43 (-6)

24% less capital invested

Capital invested by funds: $103M → $77.9M (-$25M)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
43
Holders Change
-6
Holders Change %
-12.24%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
12
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$625K
2
TAM
TFG Asset Management
Cayman Islands
+$381K
3
MS
Maven Securities
Jersey
+$160K
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$131K
5
HF
HRT Financial
New York
+$47.2K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.61M
2
BlackRock
BlackRock
New York
-$1.25M
3
Man Group
Man Group
United Kingdom
-$1.03M
4
Millennium Management
Millennium Management
New York
-$449K
5
Morgan Stanley
Morgan Stanley
New York
-$403K
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
26
Paloma Partners
Connecticut
$33K +$29.2K +27,400 New
Morgan Stanley
27
Morgan Stanley
New York
$31K -$403K -377,598 -94%
PAM
28
Panagora Asset Management
Massachusetts
$22K +$19.7K +18,466 New
KBC Group
29
KBC Group
Belgium
$7K +$6.11K +5,730 +3,371%
UBS Group
30
UBS Group
Switzerland
$7K +$6.57K +6,157 +8,796%
Bank of America
31
Bank of America
North Carolina
$6K +$5.57K +5,222 New
CG
32
Cutler Group
California
$3K – – –
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$3K +$1.12K +1,054 +53%
Rockefeller Capital Management
34
Rockefeller Capital Management
New York
$2K +$2.13K +2,000 New
Barclays
35
Barclays
United Kingdom
$1K -$1.19K -1,117 -68%
NFG
36
Next Financial Group
Texas
$1K – – –
ED
37
Exane Derivatives
France
$537 – – –
BlackRock
38
BlackRock
New York
– -$1.25M -829,567 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$53K -35,348 Closed
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
– -$40K -26,579 Closed
ProShare Advisors
41
ProShare Advisors
Maryland
– -$34K -22,483 Closed
SG Americas Securities
42
SG Americas Securities
New York
– -$33K -21,987 Closed
TRCT
43
Tower Research Capital (TRC)
New York
– -$22.7K -21,310 -99%
AG
44
Aperio Group
California
– -$30K -19,581 Closed
Citadel Advisors
45
Citadel Advisors
Florida
– -$29K -18,962 Closed
RJFSA
46
Raymond James Financial Services Advisors
Florida
– -$27K -18,000 Closed
Citigroup
47
Citigroup
New York
– -$2.31K -2,164 -99%
SPIA
48
Steward Partners Investment Advisory
New York
– -$3K -2,000 Closed
Deutsche Bank
49
Deutsche Bank
Germany
– -$821 -770 -89%
QT
50
Quantamental Technologies
New York
– -$1K -700 Closed
1
2
3

ADAP Hedge Fund Activity: Q4 2019 in Review

43 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2019, worth a combined $77.9M — down 24% from $103M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ADAP and 7 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 9 added.

The largest buyer was Renaissance Technologies, adding an estimated $625K. The largest seller was Wellington Management Group, cutting an estimated $1.61M.

  • 43 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2019, down from 49 in Q3 2019.
  • Funds reported $77.9M of Adaptimmune Therapeutics stock for Q4 2019, down 24% quarter-over-quarter.
  • 7 funds opened new Adaptimmune Therapeutics positions in Q4 2019 and 13 closed out, a net change of -6 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $625K added.
  • The largest Adaptimmune Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $1.61M sold.

Based on aggregated 13F filings for Q4 2019.